D
Biohaven Ltd. BHVN
$16.54 -$1.37-7.65%
Recommendation
Sell
Prev Close
$17.91
Volume
1,708,934
Avg Vol (90D)
1,093,800
Market Cap
$1.83B
Dividend & Yield
--
52-Week Range
$16.90 - $55.70
P/E (TTM)
--
EPS (TTM)
-$9.39
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ...
4/8/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
4/8/2025 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
4/7/2025 - Globe Newswire
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Buy" from Brokerages
4/7/2025 - MarketBeat
Biohaven (NYSE:BHVN) Hits New 12-Month Low - Time to Sell?
4/5/2025 - MarketBeat
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of ...
4/5/2025 - GuruFocus
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
4/5/2025 - PR Newswire
32,000 Shares in Biohaven Ltd. (NYSE:BHVN) Bought by Bryce Point Capital LLC
4/5/2025 - MarketBeat
JPMorgan Chase & Co. Increases Position in Biohaven Ltd. (NYSE:BHVN)
4/5/2025 - MarketBeat
Biohaven (NYSE:BHVN) Trading Up 4.4% - Should You Buy?
4/4/2025 - MarketBeat
Clearbridge Investments LLC Boosts Stock Position in Biohaven Ltd. (NYSE:BHVN)
4/4/2025 - MarketBeat
KLP Kapitalforvaltning AS Acquires Shares of 16,100 Biohaven Ltd. (NYSE:BHVN)
4/4/2025 - MarketBeat
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
4/3/2025 - Fool.com Headlines
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
4/3/2025 - Globe Newswire
Biohaven (NYSE:BHVN) Trading Down 9.9% - Should You Sell?
4/1/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/31/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/31/2025 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/30/2025 - Globe Newswire
Biohaven (NYSE:BHVN) Reaches New 12-Month Low - Should You Sell?
3/29/2025 - MarketBeat
EFG Asset Management North America Corp. Makes New Investment in Biohaven Ltd. (NYSE:BHVN)
3/27/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/26/2025 - Globe Newswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
3/26/2025 - Globe Newswire
Emerald Advisers LLC Buys Shares of 360,538 Biohaven Ltd. (NYSE:BHVN)
3/24/2025 - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Bought by Swiss National Bank
3/24/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/17/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$866.36M
EBIT (TTM)
-$874.21M
Net Income (TTM)
-$846.42M
Balance Sheet
Total Assets (Q)
$615.11M
Total Debt (Q)
$36.58M
Total Liabilities (Q)
$191.67M
Book Value Per Share (Q)
$4.18
Cash Flow
Cash from Operations (TTM)
-$582.45M
Cash from Investing (TTM)
-$244.97M
Cash from Financing (TTM)
$677.77M
Net Change in Cash (TTM)
-$149.58M
Filings
Filing Date
Monday, March 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.52
7-Day Total Return
-40.18%
30-Day Total Return
-54.60%
60-Day Total Return
-54.96%
90-Day Total Return
-63.43%
Year to Date Total Return
-55.63%
1-Year Total Return
-67.83%
2-Year Total Return
30.85%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $16.90
52-week High
Oct 08, 2024 - $55.70
Valuation
Market Cap
$1.83B - Small Cap
Enterprise Value
$1.38B
Price/Sales (TTM)
--
Price/Book (Q)
4.28
Dividends and Shares
Shares Outstanding
101.05M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biohaven.com
Phone Number
203 404 0410
Address
215 Church Street
New Haven, CT 06510
Country
United States
Year Founded
2022
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment... more
NYSE 04/08/2025 4:00PM Eastern Quotes delayed
Weiss Ratings